Intravesical Botulin Toxin-A Injections for Neurogenic Bladder Dysfunction in Children: Summary Update on Last 10...

Area of Science:

• Pediatric Urology
• Neurology
• Pharmacology

Background:

• Neurogenic bladder (NB) presents significant challenges in pediatric urology.
• Intravesical botulinum toxin-A (BTX-A) injections are a treatment option for NB, typically used after conservative measures fail and before invasive procedures.
• Consensus on optimal pediatric NB treatment remains elusive.

Purpose of the Study:

• To review and synthesize research on BTX-A bladder injections for pediatric neurogenic bladder over the past decade.
• To evaluate the efficacy, safety, and outcomes of BTX-A treatment in children with NB.
• To identify trends and inconsistencies in current treatment protocols.

Main Methods:

• A systematic review of PubMed-indexed research from the last 10 years was conducted.
• Two authors independently selected articles based on predefined inclusion criteria.
• Data extracted included patient demographics, neurological conditions, BTX-A treatment details, clinical/urodynamic parameters, adverse events, and outcomes.

Main Results:

• The review analyzed 16 studies encompassing 630 pediatric patients with NB, with a median age of 9.7 years.
• Myelomeningocele was the most common neurological diagnosis (40%).
• BTX-A injections demonstrated overall efficacy and safety in treating pediatric NB.

Conclusions:

• Intravesical BTX-A is a valuable and safe therapeutic strategy for managing neurogenic bladder in the pediatric population.
• Despite proven efficacy, significant heterogeneity exists in published treatment protocols and study standardization.
• Further research is needed to establish uniform guidelines for BTX-A use in pediatric NB.